Time and dose-effect relationships of prostaglandin E1 on pulmonary hypertension caused by rheumatic heart disease

CLC Number:

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/

[1]	. [J]. Clinical Focus, 2012, 27(13): 1149-1150.
[2]	. [J]. CLINICAL FOCUS, 2007, 22(1): 44-0.
[3]	. [J]. CLINICAL FOCUS, 2006, 21(23): 1713-1714.
[4]	. [J]. CLINICAL FOCUS, 2006, 21(15): 1093-1094.
[5]	. [J]. CLINICAL FOCUS, 2004, 19(13): 755-756.
[6]	. Clinical study on systemic embolism in patients with rheumatic heart disease [J]. CLINICAL FOCUS, 2004, 19(7): 377-379.
[7]	. Comparison of serum lipid levels with apolipoproteins in rheumatic heart disease and dilated cardiomyopathy [J]. CLINICAL FOCUS, 2004, 19(5): 244-246.
[8]	. Clinical investigation on 518 cases with rheumatic heart disease [J]. CLINICAL FOCUS, 2003, 18(19): 1096-1098.
[9]	. Risk factors of left atrial thrombus in patients with rheumatic valve disease [J]. CLINICAL FOCUS, 2003, 18(5): 249-251.
[10]	. Percutaneous balloon mitral valvuloplasty for the patients with rheumatic mitral stenosis and left atrial thrombi [J]. CLINICAL FOCUS, 2003, 18(1): 9-9.
[11]	. [J]. CLINICAL FOCUS, 2003, 18(1): 14-14.
[12]	. [J]. CLINICAL FOCUS, 2002, 17(22): 1322-1322.

PDF (PC)